Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Down 3.8% – Should You Sell?

Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) traded down 3.8% during trading on Thursday . The company traded as low as $2.23 and last traded at $2.27. 556,419 shares were traded during mid-day trading, an increase of 43% from the average session volume of 390,083 shares. The stock had previously closed at $2.36.

Analyst Upgrades and Downgrades

NAUT has been the topic of several recent research reports. Guggenheim lifted their price objective on Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nautilus Biotechnology presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Nautilus Biotechnology Stock Performance

The firm has a market capitalization of $288.47 million, a price-to-earnings ratio of -4.93 and a beta of 0.75. The firm’s 50-day moving average price is $2.58 and its two-hundred day moving average price is $2.48.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Tuesday, April 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02.

Insider Buying and Selling at Nautilus Biotechnology

In other news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total value of $11,750,000.00. Following the completion of the transaction, the insider directly owned 971,885 shares of the company’s stock, valued at approximately $2,283,929.75. This represents a 83.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 41.10% of the company’s stock.

Institutional Trading of Nautilus Biotechnology

Several institutional investors have recently bought and sold shares of NAUT. Garde Capital Inc. bought a new stake in Nautilus Biotechnology in the fourth quarter valued at $35,000. Hudson Bay Capital Management LP bought a new position in shares of Nautilus Biotechnology during the fourth quarter valued at $37,000. Qube Research & Technologies Ltd acquired a new stake in shares of Nautilus Biotechnology in the 2nd quarter valued at $45,000. Virtu Financial LLC boosted its stake in shares of Nautilus Biotechnology by 19.6% in the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock valued at $46,000 after purchasing an additional 3,849 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. acquired a new stake in shares of Nautilus Biotechnology in the 1st quarter valued at $48,000. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.